Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy



Status:Archived
Conditions:Neurology, Orthopedic
Therapuetic Areas:Neurology, Orthopedics / Podiatry
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:November 2010

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

IGF-1 Therapy and Muscle Function in Duchenne Muscular Dystrophy


The purpose of this study is to determine whether IGF-1 therapy improves or preserves muscle
function in Duchenne Muscular Dystrophy (DMD).


Detailed Description:

DMD is a progressive degenerative muscle disorder for which there is no current cure.
Glucocorticoids (GC) are often used to improve motor function and survival but have
significant side effects such as growth failure, weight gain, insulin resistance and
osteoporosis. IGF-1 stimulates both the proliferation and differentiation of skeletal muscle
cells and is thus important for muscle repair and regeneration. IGF-1 offers potential as a
therapeutic agent for DMD as it may improve or preserve motor function and reduce GC side
effects such as growth failure and insulin resistance.


We found this trial at
1
site
Cincinnati Children's Hospital Medical Center
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials